New Delhi: The wait for the COVID vaccine in the country is now coming to an end. Serum Institute will apply for an emergency use license of the coronavirus vaccine within two weeks being developed by the University of Oxford and pharma giant AstraZeneca.
Adar Poonawalla, Chief Executive Officer (CEO) of Serum Institute of India, said in a press conference about PM Narendra Modi's journey, "We discussed the strategy, about the implementation of the plan which only after obtaining the emergency usage license applicable, which will be released on the basis of the data given by us. We are in the process of officially applying before the Drug Controller General of the country. "
Asked if the company had applied for an emergency license, Poonawala said, "We are in the process of applying for an emergency use license in the next two weeks." He also said, "The person who takes the vaccine will not spread the infection. There will be no need to go to the hospital after taking the vaccine. CoviShield will also benefit in reducing mortality. It is expected to reduce hospitalization by 0%. The effect of the virus is 60%, Hospitality remains 0% in Covyshield's global trials. After the vaccine is initially distributed in India, we will focus on other COVAX countries, especially African countries. Our priority is India and COVAX countries. "
Also Read-
India vs Australia 2020, 2nd ODI: Australia posts 389/4; Smith scores ton
Prices of onion-potato changes due to impact of farmers' protest on Indus border
1 Delhi police constable and 1 Home Ministry official arrested for running Solver Gang